Christine Fritsch

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 462 citations

Pten Mutation, Somatic Pik3ca Mutations, Pharmacotherapy +18

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Pascal Furet, Vito Guagnano, Robin A. Fairhurst et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 460 citations · Full text

Medicine, Receptor Tyrosine Kinase, Immunology +7

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

Rami Rahal, Mareike Frick, Rodrigo Romero et al. · Nature Medicine · 2013 · 327 citations

Lymphoid Neoplasia, Oncology, Mantle Cell Lymphoma +8